Revenue at 30 September 2015, up by 10.2% at constant exchange rates
Guerbet third-quarter revenue up by 14.6%. Cumulative revenue totalled €343.6 million, up by 10.2%.
Guerbet is reporting a third-quarter revenue up by 14.6% at constant exchange rates. Cumulative revenue totalled €343.6 million at the end of September 2015, up by 13.6%, or +10.2% excluding exchange rate effects.
- Double-digit growth in business activity in Europe and in Other Markets
Third-quarter sales in Europe were €78 million, with a growth of 9.9% at current exchange rates, for total sales of €236.7 million in the first nine months of the year. For Other Markets, continued higher sales in the United States make up most of the quarter's growth.
- Good performance from Xenetix® and Dotarem®
Sales from the MRI segment came to €53.8 million over the quarter, for growth of 28.1%.
At the end of September, cumulative X-Ray revenue was €144.2 million (+2.8%).
The IRT segment increased of more than 40% over the past nine months.
The Imaging Solutions and Services (ISS) segment saw cumulative growth of 6.9%, for sales of €13.5 million.
- Meeting annual objectives
Following this successful third quarter, Guerbet confirms its revenue objective of €445 million (+/- 2%).